1129435-60-4
1129435-60-4 structure
- Name: Gevokizumab
- Chemical Name: IMMunoglobulin G2
- CAS Number: 1129435-60-4
- Molecular Formula:
- Molecular Weight:
- Catalog: Signaling Pathways Immunology/Inflammation Interleukin Related
- Create Date: 2018-06-04 06:50:37
- Modify Date: 2024-01-09 14:18:04
-
Gevokizumab is a potent anti-IL-1β antibody, negatively modulates IL-1β signaling through an allosteric mechanism. Gevokizumab selectively decreases the binding affinity of IL-1β for the IL-1 receptor type I (IL-1RI) signaling receptor instead of IL-1 counter-regulatory decoy receptor (IL-1 receptor type II)[1][2].
| Name | IMMunoglobulin G2 |
|---|
| Description | Gevokizumab is a potent anti-IL-1β antibody, negatively modulates IL-1β signaling through an allosteric mechanism. Gevokizumab selectively decreases the binding affinity of IL-1β for the IL-1 receptor type I (IL-1RI) signaling receptor instead of IL-1 counter-regulatory decoy receptor (IL-1 receptor type II)[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Gevokizumab (5 nM; 16 h) shows inhibitory effects of IL-1β-mediated NF-kB activation caused by the soluble receptors, sIL-1RI and sIL-1RII in HeLa cells[1]. Gevokizumab (1.85, 5.55, 16.66, and 50 nM) is a selective negative allosteric modulator which reduces the binding affinity of sIL-1RI to IL-1β[1]. |
| In Vivo | Gevokizumab (1 mg/kg; i.v.; once daily for 3 d) improves endothelial regrowth and reduces neointima formation in rats following carotid denudation[2]. Animal Model: Rat carotid denudation model in Sprague-Dawley rats (3-month0-old, 330-360 g)[2] Dosage: 1, 10 and 50 mg/kg Administration: Intravenous injection; once daily for 3 days Result: Decreased carotid intima-media thickness (IMT) in the proximal part of the denuded artery at day 28, and improved endothelial regrowth at 1 mg/kg. |
| References |
| No Any Chemical & Physical Properties |